Dog /
FDA CVM · 2025 release 1,623 reports on file

Shepherd Dog - Belgian Malinois - FDA Adverse Event Profile

Adverse-event records for Shepherd Dog - Belgian Malinois (Dog) from the FDA Center for Veterinary Medicine.

Verify with FDA CVM →
Annual adverse-event report trend Yearly FDA CVM adverse-event report counts for this breed. 168 126 84 42 0 2018 2019 2020 2021 2022 2023 2024 2025 Reports filed Death-coded reports
Annual report volume for Shepherd Dog - Belgian Malinois drawn from FDA CVM filings.

Data updated June 2026

The record at a glance

Among dog breeds, Shepherd Dog - Belgian Malinois is #83 by FDA report volume; 3.0% of its 1,623 reports (48) were death-coded.

#83
most-reported dog breed
3.0%
death-coded report share
418
Lack of efficacy (endoparasite) - heartworm - top reaction
4.4 yr
average age at report

Higher volume usually means a more popular breed, not a riskier one, compare against how common the breed is.

Total Reports

1,623

FDA CVM filings

Deaths Reported

48

of 1,623 reports

Death Rate

3.0%

death-coded share

Avg Age at Report

4.4 yr

29.2 kg avg weight

Death-Coded Outcome Share

Shepherd Dog - Belgian Malinois death-coded reports 3.0%
Cross-breed median

3.0% of 1,623 shepherd dog - belgian malinois reports involved a death outcome.

How to read this number

Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (about 4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.

Average weight at time of report: 29.2 kg (64.4 lbs)

Top Reported Reactions

Lack of efficacy (endoparasite) - heartworm 418
INEFFECTIVE, HEARTWORM LARVAE 257
Vomiting 178
Diarrhoea 91
Lack of efficacy - NOS 90
Cardiac disorder NOS 72
Lethargy (see also Central nervous system depression in 'Neurological') 70
Lack of efficacy (ectoparasite) - flea 66
Lack of efficacy (endoparasite) - hookworm 65
Seizure NOS 52
Emesis 48
Lack of efficacy (ectoparasite) - tick NOS 40
Lack of efficacy (bacteria) - Borrelia 34
Decreased appetite 31
Emesis (multiple) 30

Most Referenced Drugs

Ivermectin + Pyrantel As Pamoate Salt 300
Milbemycin Oxime + Spinosad 229
Moxidectin 176
Pyrantel Pamoate;Sarolaner 149
Milbemycin Oxime + Praziquantel 96
Afoxolaner 89
Fluralaner 13.64% 12-Week Chew 72
Bedinvetmab 47
Milbemycin Oxime 40
Fluralaner Chew Tablets 38
Carprofen 36
Spinosad 32
Melarsomine Dihydrochloride 32
Ivermectin, Pyrantel 29
Ivermectin/Pyrantel Pamoate Chewable 272Mcg/652Mg 29

Outcome Breakdown

Ongoing
566 (36.8%)
Outcome Unknown
507 (32.9%)
Recovered/Normal
297 (19.3%)
Recovered with Sequela
122 (7.9%)
Died
24 (1.6%)
Euthanized
24 (1.6%)

Gender Distribution

Male 950 (58.5%)
Female 641 (39.5%)
Unknown 29 (1.8%)
Mixed 3 (0.2%)

Reports by Year

Year Reports Trend
2010 33
2011 70
2012 57
2013 56
2014 59
2015 97
2016 95
2017 88
2018 105
2019 123
2020 128
2021 130
2022 131
2023 160
2024 168
2025 123

Shepherd Dog - Belgian Malinois Pet Health Insights

Shepherd Dog - Belgian Malinois accounts for 1,623 FDA adverse event reports, ranking #83 by volume among dog breeds, with 48 reports (3.0%) coded as a death outcome. Mean age at report: 4.4 years, average weight 29.2 kg (64.4 lbs).

Top reported signs: Lack of efficacy (endoparasite) - heartworm (418), INEFFECTIVE, HEARTWORM LARVAE (257), Vomiting (178). Most-referenced drug: Ivermectin + Pyrantel As Pamoate Salt (300 reports), followed by Milbemycin Oxime + Spinosad (229) and Moxidectin (176).

Outcome coding on 1,540 status-recorded reports is dominated by Ongoing (36.8%). Annual submissions ranged 2,010-2,025 across 16 years on file.

Dog Breeds With a Similar Report Volume

Frequently Asked Questions

How many FDA adverse event reports involve Shepherd Dog - Belgian Malinois?
There are 1,623 adverse event reports involving Shepherd Dog - Belgian Malinois in the FDA database, with 48 reports involving death (3.0% death rate). Shepherd Dog - Belgian Malinois ranks #83 by report volume.
What are the most common adverse reactions reported for Shepherd Dog - Belgian Malinois?
The most commonly reported adverse reactions for Shepherd Dog - Belgian Malinois are Lack of efficacy (endoparasite) - heartworm (418 reports), INEFFECTIVE, HEARTWORM LARVAE (257 reports), Vomiting (178 reports), Diarrhoea (91 reports), Lack of efficacy - NOS (90 reports).
What drugs are most frequently associated with Shepherd Dog - Belgian Malinois adverse events?
The drugs most frequently referenced in Shepherd Dog - Belgian Malinois adverse event reports are Ivermectin + Pyrantel As Pamoate Salt (300 reports), Milbemycin Oxime + Spinosad (229 reports), Moxidectin (176 reports), Pyrantel Pamoate;Sarolaner (149 reports), Milbemycin Oxime + Praziquantel (96 reports).
What is the average age of Shepherd Dog - Belgian Malinois in adverse event reports?
The average age of Shepherd Dog - Belgian Malinois at the time of adverse event reports is 4.4 years, with an average weight of 29.2 kg (64.4 lbs).
Does a high number of adverse event reports mean Shepherd Dog - Belgian Malinois is unhealthy?
No. FDA adverse event reports are voluntarily submitted and do not prove causation. Popular breeds with more veterinary visits tend to have more reports. The data reflects reporting patterns, not actual incidence rates. Always consult a veterinarian for health decisions.
Where does this Shepherd Dog - Belgian Malinois safety data come from?
All data comes from the FDA Center for Veterinary Medicine's adverse event reporting system. Pet owners, veterinarians, and manufacturers voluntarily submit reports about adverse events potentially linked to animal drugs and other products.

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. Breed figures are computed directly from FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.